19 June 2013
Keywords: nycomed, pozen, sign, licensing, deal, mt, denmark
Article | 07 July 2003
Nycomed of Denmark has obtained the exclusive marketing rights in Denmark, Sweden, Norway and Finland for MT 100, USA-based Pozen's oral
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 July 2003
18 June 2013
© 2013 thepharmaletter.com